Introduction
The concept of a placenta clinic, providing comprehensive medical and surgical care for a wide spectrum of disorders, has developed in several academic centers worldwide over the past 20 years. Success is based on interdisciplinary management in a hospitalbased tertiary care environment led by maternal-fetal medicine subspecialists working with nurse practitioners, internal medicine subspecialties and gynecologic surgeons with support from neonatal pediatrics, perinatal pathology, magnetic resonance imaging (MRI), reproductive genetics, obstetrical anesthesia, and perinatal psychiatry. These resources offer an enhanced model of care in the context of suspected fetal growth restriction (FGR), and are especially useful for women with preexisting hypertension, complex obstetrical backgrounds, or other medical comorbidities that place women at higher risk of placental pathology. By placing a focus on the prenatal diagnosis of placental diseases, this approach aids the distinction between a healthy small for gestational age (SGA) fetus and a fetus at risk of perinatal complications due to FGR. Comprehensive electronic medical records are a key component of care, ensuring accurate interpretation of gestational age-dependent ultrasound observations, integration of ambulatory care, and seamless transition into inpatient care, delivery, and postpartum follow-up. Integration of multiparameter screening for FGR is an emerging important component of available software. 1 Clinic-based website resources can also be used to enhance Effective detection and management of fetal growth restriction is relevant to all obstetric care providers. Models of best practice to care for these patients and their families continue to evolve. Since much of the disease burden in fetal growth restriction originates in the placenta, the concept of a multidisciplinary placenta clinic program, managed primarily within a maternal-fetal medicine division, has gained popularity. In this context, fetal growth restriction is merely one of many placenta-related disorders that can benefit from an interdisciplinary approach, incorporating expertise from specialist perinatal ultrasound and magnetic resonance imaging, reproductive genetics, neonatal pediatrics, internal medicine subspecialties, perinatal pathology, and nursing. The accurate diagnosis and prognosis for women with fetal growth restriction is established by comprehensive clinical review and detailed sonographic evaluation of the fetus, combined with uterine artery Doppler and morphologic assessment of the placenta. Diagnostic accuracy for placenta-mediated fetal growth restriction may be enhanced by quantification of maternal serum biomarkers including placenta growth factor alone or combined with soluble fms-like tyrosine kinase-1. Uterine artery Doppler is typically abnormal in most instances of early-onset fetal growth restriction and is associated with coexistent preeclampsia and underlying maternal vascular malperfusion pathology of the placenta. By contrast, rare but potentially more serious underlying placental diagnoses, such as massive perivillous fibrinoid deposition, chronic histiocytic intervillositis, or fetal thrombotic vasculopathy, may be associated with normal uterine artery Doppler waveforms. Despite minor variations in placental size, shape, and cord insertion, placental function remains, largely normal in the general population. Consequently, morphologic assessment of the placenta is not currently incorporated into current screening programs for placental complications. However, placental ultrasound can be diagnostic in the context of fetal growth restriction, for example in Breus' mole and triploidy, which in turn may enhance diagnosis and management. Several examples are illustrated in our figures and supplementary videos. Recent advances in the ability of multiparameter screening and intervention programs to reduce the risk of severe preeclampsia will likely increase efforts to deliver similar improvements for women at risk of fetal growth restriction. Placental pathology is important because the underlying pathologies associated with fetal growth restriction have a wide range of recurrence risks. Rare conditions such as massive perivillous fibrinoid deposition or chronic histolytic intervillositis may recur in >50% of subsequent pregnancies. Postpartum care in a placenta-focused program can provide effective counseling for modifiable maternal risk factors, and can assist in planning future pregnancy care based on the pathologic basis of fetal growth restriction. patient understanding of placentarelated diseases. 2 
Diagnostic evaluation in suspected FGR
Review of pregnancy history and prior test results Fetal growth assessment begins with assignment of gestational age, ideally using ultrasound measurements from the first or early second trimesters.
Subsequent biometry data are then used to review the trajectory of growth. Several risk factors for SGA birth or FGR that include the use of assisted reproductive technologies, loss of a co-twin, heavy first-trimester vaginal bleeding, increased nuchal translucency, abnormal screening analyte data, and crown-rump length discrepancy are listed in Table 1. 1,3-9 Accurate dating is essential for establishing the subsequent diagnosis of either a healthy SGA fetus or a fetus with growth restriction. 10 Relevant maternal comorbidities should be noted and addressed, in particular chronic hypertension, diabetes, and elevated body mass index. Prior uterine surgeries are relevant in subsequent planning of mode of delivery. Obtaining a travel history (to Zika viruseaffected areas) is also relevant to the evaluation of a suspected FGR pregnancy. 11 Maternal substance use of alcohol, marijuana, cocaine, and cigarette smoking all increase the risk of low birthweight (<2500 g) or SGA deliveries (Table 2) . [12] [13] [14] [15] Finally, the results of any additional pregnancy tests, such as invasive microarray genetic data, fetal anatomical assessment, and previous pregnancy reports (especially for placental pathology), are reviewed.
Biometry, anatomy, and amniotic fluid Ultrasound imaging begins with fetal biometry and a review of anatomy. A variety of formulas exist to estimate fetal weight. 16 Appropriate selection among available formulas is important when there is fetal asymmetry (elevated head circumference/abdominal circumference ratio with short femurs) at <33 weeks with abnormal umbilical artery Doppler, 17 because in this context incorporation of femur length (FL) can lead to significant (>10%) underestimation of fetal weight. In a study of 43 early-onset FGR pregnancies delivered at <33 weeks, incorporation of FL underestimated birthweight by 8% when 27 weeks, and by 15% at 28-33 weeks. 18 Therefore, selecting an appropriate formula without FL is important when deriving the estimated fetal weight in suspected early-onset FGR pregnancies that have an elevated head circumference/abdominal circumference ratio for gestational age. A second important consideration is gestational age assignment in early-onset FGR in the absence of first-trimester ultrasound dating; in this context, gestational age was accurately predicted throughout the second trimester (AE3 days in 97.5%, n ¼ 40) by measurement of the transcerebellar diameter, 19 which is therefore an important measurement to make. Amniotic fluid volume assessment is relevant to making a diagnosis of FGR; oligohydramnios is a feature of placenta-mediated FGR, while some fetal malformations and chromosomal abnormalities are associated with excess amniotic fluid.
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Careful reevaluation of fetal anatomy is necessary for evaluation of all nonplacental causes of FGR since, at a population-based level, congenital birth defects confer a 2.6 relative risk (RR) for birth of an SGA neonate. 21 In this context, some findings, such as echogenic bowel 22 or short FL, may be consistent with placental FGR rather than aneuploidy or other fetal causes of FGR 18, 23 ; short femurs associated with FGR may be distinguished from most skeletal dysplasias by noting normal bone morphology, continued femur elongation, and normal shape in the remaining long bones, chest wall, and skull. Careful evaluation of cardiac anatomy is important, since a range of congenital cardiac malformations are associated with suspected FGR. In a population-based study, congenital heart disease was associated with birthweight <10th percentile, especially tetralogy of Fallot (RR, 4.6; 95% confidence interval [CI], 3.1e6.8), atrial septal defect (RR, 3.8; 95% CI, 3.4e4.2), and coarctation of the aorta (RR, 3.5; 95% CI, 2.4e5.1). 21 Some cardiac defects specifically reduce fetal brain growth, especially hypoplastic heart syndrome and large ventriculoseptal defects. 24 A range of fetal brain abnormalities is more common in FGR pregnancies. One third of triploidy fetuses diagnosed in the second trimester exhibit bilateral ventriculomegaly. 25 Acquired brain injury is surprisingly common in early-onset FGR. In a prospective single-center series of 90 FGR pregnancies delivered at 28-34 weeks with abnormal umbilical artery Doppler, 40% had immediate postnatal evidence of brain injury (intraventricular hemorrhage, periventricular leukomalacia) in comparison with 12% in a gestational age-matched control group. 26 Vasodilation of the middle cerebral artery accompanied by 27 and may be able to detect ischemic brain injury by diffusion-weighted imaging. 28 
Uterine artery Doppler
The uterine arteries selectively vasodilate during pregnancy, directing the increased cardiac output to the uterus. Doppler assessment of the proximal arteries demonstrates this phenomenon, with declining mean pulsatility index (PI) values as pregnancy advances; we use the reference range provided by Gomez et al 29 for clinical interpretation of the mean PI value across gestation. Uterine artery Doppler (UtAD) assessment is an attractive concept to screen for FGR in the second trimester, 30 since the majority of early-onset FGR pregnancies exhibit a postnatal pathology diagnosis of maternal vascular malperfusion (MVM) of the placenta, associated with bilateral high-resistance notched waveforms. 31 Normally the waveform is assessed on both sides, but can be omitted on the opposite side of a lateral placenta to avoid false-positive mean PI results. 32 In large cohort studies of unselected women, UtAD achieves insufficient precision as a screening test to deliver improved outcomes for suspected FGR pregnancies. The Uterine Test to Detect Preeclampsia (UTOPIA) trial randomized 11,667 to a fetal anatomical ultrasound with or without UtAD at 19-23 weeks, where women in the screened group with an abnormal UtAD (mean PI >90th percentile) received enhanced surveillance. 30 Moderate sensitivity (60%) was achieved for the prediction of FGR and delivery <34 weeks, with sensitivity reducing to 24% for FGR and delivery !34 weeks, and 18% for SGA births. Despite significantly greater interventions such as corticosteroid use (RR, 1.79; 95% CI, 1.4e2.3) and induction of labor (RR, 1.36; 95% CI, 1.07e1.72), no significant improvements in either perinatal or maternal outcomes was demonstrated. A similar conclusion was reached in the Nulliparous Pregnancy Outcomes Study of 8024 women, where UtAD was performed at 16-21 weeks as a screening test for SGA birth across all gestational ages at the fifth centile, achieving a modest 45% sensitivity using a mean PI !0.98.
33 A smaller US cohort made similar conclusions. 34 UtAD may be incorporated within multiparameter models, comprising clinical risk factor and biomarkers, to predict placental disease or associated adverse clinical outcomes in the second trimester, [35] [36] [37] but are not sufficiently precise to recommend for use in low-risk pregnancies.
UtAD may likewise be integrated into similarly designed first-trimester screening algorithms to predict adverse pregnancy outcomes related to SGA birth. 38 This approach may become more popular following the recent publication of a substantial reduction (odds Normal placental sonographic findings in second trimester A, In optimal placental development, placenta is circular, with central 3-vessel cord. Umbilical artery branches (blue circles) ramify across chorionic plate in dichotomous fashion (shown in 1 quadrant). Individual villous trees form below each branch point and therefore form even in periphery of disc (open circles). B, Sonographic measurement of maximum placental length at 21 weeks using curvelinear method at basal plate (þ e þ), and maximum placental thickness (x e x) at 21 weeks of gestation. See Supplementary Video 1. Reference range for placental dimensions at 20þ0 to 23þ6 weeks' gestation is shown in Table 3 .
Kingdom. Diagnosis and management of FGR. Am J Obstet Gynecol 2018. 39 In a diagnostic setting, UtAD has prognostic utility in women with abnormal biomarker data in the second trimester. 40, 41 Abnormal UtAD may normalize during the second trimester, which is a favorable observation since outcomes are improved in comparison with women that exhibit persistently abnormal waveforms. 42 Third-trimester UtAD is not an effective screening tool in unselected pregnancies, 43 but may aid identification of a placental basis for suspected FGR.
Placental morphologic assessment Visualization of the placenta by ultrasound is a logical adjunct to UtAD because a majority of placentas examined following extreme preterm births with preeclampsia or FGR are small and grossly abnormal. [44] [45] [46] The simplest method uses 2-dimensional ultrasound to measure maximum placental length, thickness, overall placental shape, and cord insertion. 37, [47] [48] [49] Normal placental findings in the second trimester are summarized in Table 3 37 and illustrated in Figure 1 and Supplementary Video 1. Descriptive associations have been demonstrated between gross abnormalities in placental size, shape, and cord insertion and adverse perinatal outcomes including FGR. 50, 51 Increased placental thickness confers an increased risk of perinatal complications, but the implication of this finding depends on the underlying pathology. A single-center Japanese study in 3183 women demonstrated an increased OR (1.8; 95% CI, 1.2e2.8) of SGA at birth where thickness was >95th centile for gestation, but did not report placenta pathology data. 52 Placental morphologic assessment can improve screening accuracy for FGR but is of insufficient value to justify its cost in low-risk populations, 36 since variations in placental size and shape have relatively weak associations with birthweight 37, 53 ( Figure 2 ). In high-risk pregnancies with bilateral abnormal UtAD waveforms at 19-23 weeks, the finding of Minor variations in placental anatomy that impair overall efficiency (fetalplacental weight ratio at birth)
A, Eccentric cord insertion: as cord insertion is placed more eccentrically chorionic tissue on opposing edge may become less vascularized due to attenuated chorionic plate vascular branching in opposite quadrant. B, Elliptical placenta: similar phenomenon may occur at lateral margins of elliptical placenta. Such alterations in placental shape and cord insertion alone account for only w10% of variation found in birthweight. ajog.org Expert Reviews abnormal placental shape (thickness/ length ratio >0.5 or thickness >4 cm) increased the odds of early-onset FGR (OR, 4.7; 95% CI, 1.4e15.1). 54 Three-dimensional ultrasound is a more complex approach, but can derive placental volume and shape in early pregnancy at the time of the nuchal translucency examination. 55, 56 A recent systematic review of 5 studies (302/5411 pregnancies with a subsequent diagnosis of SGA) using 3-dimensional placental volume to predict SGA birth showed inadequate screening test characteristics (sensitivity 25%, specificity 90%). 57 The method has similar performance characteristics to second-trimester UtAD to screen for FGR. 58 Presently, the assessment of placental morphology is not recommended in low-risk pregnancies, since variations in size and shape are common in normal pregnancy. The Collaborative Perinatal Project involving 24,152 births in the United States demonstrated that placental morphological characteristics observed following birth accounted for 39% of birthweight variation. 59 Examples of minor sonographic variations are illustrated in Supplementary Videos 2 to 4.
Mechanisms of placental injury
The most common mechanism of pathologic injury to the placenta resulting in FGR is via ischemia-reperfusion insults to the developing placental villi. 60 This concept was recently reviewed in detail. 61 The pathophysiology is initiated by failed physiologic transformation of the spiral artery branches of the uteroplacental arteries, 62 restricting maternal blood flow into the intervillous space. 63 This state of MVM is identified sonographically by the combination of a small placenta and bilateral abnormal UtAD waveforms. 37, 54 Persistent ischemiareperfusion damages the developing placental villi, causing the histologic features of MVM, which include multifocal infarction 31, 45, 64 and formation of syncytial knots, with excess production and secretion of the antiangiogenic protein soluble fms-like tyrosine kinase (sFlt)-1 in syncytial knots 65, 66 and suppression of syncytiotrophoblast secretion of the proangiogenic placenta growth factor (PlGF). 67, 68 Consequently, abnormal circulating angiogenic ratios of sFlt-1 and PlGF correlate with the extent of placental MVM pathology. 69 However, combining angiogenic factors with UtAD to screen for FGR in early pregnancy in unselected women does not currently achieve clinically useful diagnostic precision; in a Spanish 1:2 matched case-control study, 24/46 SGA births were predicted in a model combining ultrasound and PlGF (sensitivity 52% at 10% false-positive rate). 38 
FIGURE 4
Intervillous thrombosis A, Ultrasound image of placenta showing echogenic cystic lesion; note crenated white rim surrounding black center (arrowhead). B, Following fixation and serial sectioning, this lesion is identified as intervillous thrombus. Note laminated layers of blood (arrowhead). C, Corresponding hematoxylin-eosin photomicrograph. Note lesion is within intervillous space of placental parenchyma. Isolated intervillous thrombi are common and of no functional significance. If numerous, they may contribute to pathogenesis of fetal growth restriction. Contrast with infarction ( Figure 3) , which is associated with decidual vasculopathy of basal plate (BP). See Supplementary Video 6. Multifocal placental infarction is found following delivery in almost 80% of early-onset FGR pregnancies with abnormal UtAD waveforms, implying substantial loss of functional placental tissue. 31 The ability to effectively detect widespread placental injury in this context may be of prognostic importance. One retrospective series of 60 early-onset FGR pregnancies demonstrated this concept by predicting stillbirth (17/21, sensitivity 81%, positive predictive value [PPV] 52%) when placental morphology and UtAD waveforms were both abnormal. 44 However, placental infarcts are challenging to identify using ultrasound because they are solid, and thus relatively similar in appearance to normal placental tissue. In a subsequent study of 60 high-risk pregnancies with abnormal UtAD, where placental infarction was found in 24/43 (56%) of placentas examined after delivery, the anticipated sonographic abnormality (echogenic basally located lesions) (Figure 3 and Supplementary Video 5), found in 15 placental images, had only a 33% PPV (21% sensitivity) for infarction. 54 By contrast, less pathologically important lesions such as intervillous thrombi are more readily identified as they have a crenated white rim and a black center indicating laminated hemorrhage ( Figure 4 and Supplementary Video 6), hence their description as echogenic cystic lesions. 70 Measurement of maternal serum PlGF in this setting may aid the interpretation of suspicious placental ultrasound findings, especially if UtAD is abnormal. Given the inherent variations in placental size and shape, the prenatal diagnosis of MVM placental pathology is most confidently made using a combination of abnormal UtAD and a small or morphologically abnormal placenta, and may be supported by low (<100 pg/mL) or very low (<12 pg/mL) maternal PlGF levels ( Figure 5 ). 71 Major retroplacental hemorrhage (abruption) is readily identifiable by ultrasound when large, but in practice is rarely observed because the disruption of Chronic placental abruption complicating fetal growth restriction at 33 weeks' gestation Patient presented to triage with reduced fetal movements but no abdominal pain. A, Ultrasound examination showed 3 areas of placental separation (arrowheads). Absent end-diastolic flow velocity was noted in umbilical arteries and nonstress test was reactive. Patient was admitted and corticosteroids were given. B, Cesarean delivery was performed >24 hours due to severe fetal heart rate deceleration in response to Braxton-Hicks contraction. C, Retroplacental hematomas were found at delivery (arrows). D, Placenta was small (225 g and third-fifth percentile at 33 weeks) with peripheral cord insertion 1.7 cm from disc margin and maternal surface was disrupted by hematomas (arrows). E, Low-power hematoxylin-eosinestained micrograph showing maternal hemorrhage (h) compressing overlying placental villi (v). See Supplementary Video 7.
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ajog.org Expert Reviews the maternal-fetal interface triggers a clinical emergency (Supplementary Video 7). Small retroplacental hematomas may evolve chronically and be visible by ultrasound ( Figure 6 ). Hemorrhage may also be found in the placental margins, but should be distinguished from the physiologic marginal sinus where intervillous blood reenters the systemic venous circulation (Supplementary Video 2) . Rarely, hemorrhage may be seen where large portions of the membranes detach from the uterine wall. 72 The perinatal risk from this range of placental lesions depends upon the amount of residual normally functioning placental tissue, combined with knowledge of the uterine and umbilical arterial Doppler waveforms. A good example of this concept is in the diagnosis and evaluation of prognosis in Breus' mole, a condition associated with severe FGR, where layers of hemorrhage accumulate directly under the chorionic plate, underlying at least 50% of the chorionic plate surface 73 ( Figure 7 and Supplementary Video 8). In this scenario, the parallel observation of normal placental villous tissues below the laminated blood is a favorable prognostic sign for perinatal survival. 73 The site of major hemorrhage is also relevant, as it may be entirely within the membranes, away from the placental disc, or alternatively may physically disrupt placental attachment.
Another diagnostic placental abnormality is the typical findings in triploidy, with increased thickness and a uniform microcystic appearance accompanied by severe asymmetric early-onset FGR. 74 
Chorion regression
Progressive tissue infarction is a characteristic manifestation of the MVM disease category, but is only one manifestation of the disease spectrum. A second major disease process in MVM is termed "chorion regression." 75 This refers to poor early formation of the definitive placenta (chorion frondosum) at the expense of the membranes (chorion leave). 76 The reduced placental attachment site is then associated with low levels of pregnancy-associated plasma protein-A at the 11-to 13-week first-trimester screening window 77 and may evolve to reveal a small placenta with an eccentric or 2-vessel cord (Figure 8 and Supplementary Video 9). In this setting, as pregnancy advances, the placenta may become "wobbly" or "floppy" due to poor development of the placental villi, likely corresponding to the histologic appearance of distal villous hypoplasia (Supplementary Video 10) or may even become hyperinflated, appearing very large with an acutely convex chorionic plate due to distension of the intervillous space by maternal blood 78 ( Figure 10 and Supplementary Video 11).
Circulating proangiogenic and antiangiogenic placenta-derived proteins The circulating proangiogenic placentaderived protein, PlGF, is an important new clinical test that is becoming more available, as well as more widely used to treat women with suspected preeclampsia, given its superior diagnostic accuracy and positive health economic analysis data from the United Kingdom 79,80 and the United States. [81] [82] [83] These tests have the potential to improve the diagnosis and management of pregnancies with suspected FGR due to the association of low circulating PlGF is associated with placenta-mediated FGR. 71 Normal circulating PlGF rises progressively during pregnancy to a plateau around 22 weeks. 71 In the second trimester, low levels of PlGF have superior screening performance in comparison with many potential biomarkers to predict placenta-related complications. 84 In a prospective cohort of 274 women with suspected preeclampsia presenting at 20-34 weeks' gestation, low circulating PlGF (<100 pg/mL) had high sensitivity to detect SGA births (n ¼ 96) below third customized birthweight centile (sensitivity 93%, negative predictive value [NPV] 90%), which was superior to fetal weight estimation by ultrasound (sensitivity 71%, NPV 79%). 85 An earlier multicenter study by the same group, of 592 women with reduced symphysisfundal height measurements, found that combining PlGF with ultrasound biometry increased the sensitivity from 58-69% for the detection of customized growth at the third centile (with the same 93% NPV). 86 As an adjunct to multiparameter screening for placental dysfunction in the second trimester, PlGF offers only modest gains and is therefore not recommended in low-risk pregnancies. 37, 87 PlGF testing in the context of FGR may be augmented by comeasurement of the sFlt-1 soluble receptor antagonist to vascular endothelial growth factor. Combined together as a ratio test, these biomarkers are predictive of the placental pathology termed "maternal vascular malperfusion." 69 In a recent Japanese cohort of 34 normotensive preterm FGR cases, an elevated sFlt-1/PlGF ratio (>86) predicted subsequent pregnancy duration, with only 42% (vs 92% with a ratio <86) remaining pregnant 14 days later. 88 In a cohort of 110 subjects with suspected preeclampsia at <34 weeks, a high sFlt-1/PlGF ratio was strongly predictive of adverse outcomes. 89 The ongoing European EVERREST cohort study will determine the prognostic value of PlGF among a range of potentially useful prognostic markers of severe FGR identified <27 weeks' gestation. 90 Safety of corticosteroids in early-onset FGR Consideration of corticosteroid administration for fetal lung maturation is an important component of management in FGR, especially for patients with more Placental deflation following delivery A, Normal placenta is expanded in vivo by perfusion of intervillous space via spiral arteries and chorionic and basal plates are maintained in parallel by subset of villous trees that anchor to basal plate (5 anchoring villi). B, Subset of pregnancies with chorion regression exhibit placental hyperinflation whereby chorionic plate bulges dramatically into uterine cavity. Following delivery, expanded structure collapses and pathologic examination often shows features of distal villous hypoplasia, therefore loss of normal anchoring villi needed to contain normal placental shape. This phenomenon develops during second trimester, confounding utility of placental volume as component of screening for fetal growth restriction. See Supplementary Videos 10 and 11. severe early-onset disease associated with hypertension and abnormal umbilical artery Doppler, and now including women identified with very low PlGF (<12 pg/mL) 71, 85 or abnormal sFlt-1/PlGF ratios. 69, 88 Corticosteroids pose a specific challenge in the context of severe FGR with abnormal umbilical artery and fetal Doppler waveforms. In sheep, fetal hypoxemia is associated with lactic acidosis, 91 which is exacerbated directly following steroid administration. 91 The human preterm FGR fetus is also at risk of lactic acidosis, 92 especially if fetal ductus venosus Doppler waveforms are abnormal. 93 Consequently, if metabolic acidosis is present, it may be exacerbated following maternal betamethasone administration. Curiously, >50% of FGR fetuses with absent enddiastolic flow in the umbilical arteries will exhibit a temporary improvement in umbilical artery Doppler waveforms in response to steroid administration, which is a favorable sign and may persist for 7-10 days. 94 In 1 study of 19 FGR fetuses, 10 exhibited a favorable umbilical artery Doppler response, whereas in the remaining 9 cases, 5 showed no improvement, 2 had a subsequent still birth, and 2 had severe fetal acidosis at cesarean delivery. 95 A more recent larger study of 93 fetuses showed that a third will not show any improvement in umbilical artery Doppler following steroid administration, and have a worse prognosis than the majority with improvements in end-diastolic flow velocity. 96 We interpret these data to imply that enhanced fetal monitoring, either daily as an inpatient, or >48 hours in an ambulatory setting, is justified when administering corticosteroids in this context. Ideally, all early-onset FGR fetuses should receive prenatal steroids prior to delivery; rarely this is not possible, for example if spontaneous decelerations occur due to placental abruption ( Figure 6 ).
Social work and mental health support
Women with preterm FGR pregnancies, along with their families, may be subjected to substantial emotional stress, particularly when the fetal prognosis appears poor or highly uncertain. Preexisting poor mental health may exacerbate these concerns and are considered to be significant comorbidities in FGR pregnancies. 97, 98 In our experience, around 25% of our placenta clinic patients at risk of FGR access our perinatal mental health services. Continuity of psychosocial care into the postpartum period is important because of the uncertain neonatal prognosis in preterm FGR birth. Dedicated clinic nurse practitioners can provide this ongoing support prior to a 6-to 8-week postpartum visit, when clinical issues summarized in Table 2 can be addressed. 
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Importance of placental pathology MVM placental pathology Placental pathology may be very informative in FGR by providing an understanding of the pathogenic mechanisms underlying growth restriction. International consensus was recently achieved on nomenclature and diagnostic criteria relevant to FGR. 99 The most common placental pathology diagnosis in FGR is MVM, a disease category defined by findings that include a small placenta, the presence of infarcts (Figure 3) , and histologic abnormalities of the placental villi, including syncytial knot formation and distal villous hypoplasia (Figures 5,  8, and 9) . A recent prospective cohort study of 856 healthy nulliparous women noted an 8% incidence of MVM, although interestingly only 50% of affected pregnancies had an adverse pregnancy outcome. 37 Multiple diagnostic features of MVM increased the PPV for FGR, consistent with recent cohort data from Detroit, where the severity of FGR and degree of imbalance in circulating angiogenesis-regulating proteins correlated with the severity of MVM. 69 The majority of placentas following delivery for severe FGR, especially with coexistent preeclampsia, will show MVM. 31 In subsequent pregnancies, low-dose aspirin treatment (150 mg/day) may not reduce the risk of FGR; however, it signficantly reduces the risk of recurrent preterm preeclampsia. 39 Placental pathology no longer guides considerations to prescribe lowmolecular-weight heparin (LMWH) in subsequent pregnancies following a diagnosis of placental MVM. LMWH has formerly been prescribed on the basis of being considered a placental anticoagulant, but in 1 pilot randomized control trial it had no effect on placental pathology. 100 Furthermore, maternal genetic thrombophilia is not associated with placental infarction 101 and is no longer considered pathogenic in the context of FGR. 102 Two recent highquality randomized controlled trials indicate that LMWH confers no additional benefit in addition to aspirin for the prevention of FGR associated with the risk of recurrent preeclampsia. 103, 104 Non-MVM placental disease Screening programs for preeclampsia 39 and FGR 38 incorporate UtAD assuming that impaired uteroplacental blood flow is a unifying underlying disease pathogenesis. However, as illustrated in Figures 8 to 10 and in Supplementary Videos 9 to 11, significant FGR and associated placental pathology may occur with normal UtAD waveforms. In a single-center retrospective cohort study of 196 pregnancies with earlyonset FGR, 10% exhibited normal UtAD waveforms and their placentas at delivery were significantly more likely to show massive perivillous fibrinoid deposition (MPVFD) 105 (also called "maternal floor infarction") (21% vs 7%) or chronic intervillositis 106 (16% vs 1%) compared to women with bilateral Fetal thrombotic vasculopathy with mild fetal growth restriction at 38 weeks of gestation At cesarean delivery, newborn had patchy skin necrosis involving arm. Review of placental pathology revealed A, fetal surface vessels suspicious for thrombosis and B, placental cross-section with C, corresponding hematoxylin-eosin (H&E) histology showing thrombosis within chorionic plate vessel. D, Slightly pale basal region of same placental cross-section (note that central red band is fixation artifact) shows E, corresponding H&E histology demonstrating avascular villi in distal/basal portions of villous tree beneath occluded vessel. ajog.org Expert Reviews abnormal UtAD waveforms. 31 Both are rare placental diseases but have a high recurrence rate >70%, 107, 108 considerably greater than for MVM (Figure 10) . No effective treatment plan in future pregnancies has been developed for chronic intervillositis, although pravastatin may be effective for MPVFD.
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Since neither is a perfusion-related disorder, the demonstration of normal midpregnancy UtAD waveforms will not exclude disease recurrence. Interestingly, maternal serum PlGF was demonstrated to be substantially depressed at 20-30 weeks in 11 pregnancies subsequently shown to have MPVFD following delivery. 110 Another non-MVM, nonperfusion-related placental pathology is villitis of unknown etiology, 111 which shows recurrence rates of 10-37%, and is more likely to be recurrent when severe and high grade. [111] [112] [113] In contrast, lowgrade villitis of unknown etiology affecting a small proportion of villi is relatively common and typically has no clinical implications. Any of these 3 diagnoses will help inform counseling about recurrence rates and prognosis, and in the context of recurrent pregnancy losses with documented MPVFD or chronic histiocytic intervillositis, discussion of future pregnancy options could include in vitro fertilization and surrogacy for women with recurrent losses despite trying all available medical options.
A final disease category associated with FGR is fetal vascular malperfusion (previously called "fetal thrombotic vasculopathy") where portions of the placental villous tree lack fetal vascular perfusion. A major cause of fetal vascular malperfusion is intermittent or partial cord compression resulting in scattered thrombosis of regions of the distal vascular tree 114, 115 ( Figure 11 ). Rarely, cord obstruction can be identified by ultrasound. Since most cord anomalies and entanglement are considered sporadic, 116 the recurrence risk for FGR in this context is minimal.
Placental health screening to direct care in a future pregnancy When FGR occurs in the context of a known or presumed MVM, low-dose aspirin each evening starting at 12 weeks' gestation is recommended for any future pregnancy, especially if preeclampsia was present, since at-risk women given aspirin 150 mg/d had a substantial reduction in recurrence of preterm-onset preeclampsia. 39 Interestingly, this large trial demonstrated no reduction in the risk of FGR (at the third or fifth centiles for birthweight), although earlier meta-analysis data predicted that aspirin would prevent FGR. 117 Therefore, the most recent evidence suggests that aspirin may be ineffective in reducing the recurrence risk of normotensive FGR. 39 Likewise, 2 recent trials exploring the adjunct use of prophylactic doses of LMWH found no reduction in the rates of recurrence of preterm preeclampsia or coexistent FGR for at-risk populations. 103, 104 Also, the vasodilatory effect of the drug sildenafil was shown in a randomized control trial to be ineffective in preventing severe FGR in high-risk women. 118 Additional drugs with potential to prevent severe preeclampsia, and therefore potentially any associated FGR, include proton pump inhibitors, 119 statins, 120 metformin, 121 hydroxychloroquine, 122 and melatonin. 123 With the exception of melatonin, none have been shown to prevent FGR. 124 -
